Abstract
Human epidermal growth factor receptor 2 (HER2) gene amplification or protein overexpression (HER2+) occurs in many gastrointestinal (GI) cancers, and HER2-targeting strategies are improving outcomes. Tucatinib (TUC), approved in multiple regions for HER2+ metastatic breast cancer, is a highly selective HER2-directed tyrosine kinase inhibitor with minimal EGFR inhibition. In patient (pt) derived xenograft models of HER2+ tumors, TUC + trastuzumab (T) showed superior anti-tumor activity compared with either agent alone (Kulukian 2020).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
